Search

Displaying results 4201 - 4210 of 8517 in total
  1. Drug

    Streptococcus pneumoniae type 19f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10336
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  3. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease.

  4. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

  5. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.

  6. Drug

    Dexibuprofen

    go.drugbank.com/drugs/DB09213
    ApprovedWithdrawn

    Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].

  7. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]

  8. Drug

    BMS-817399

    go.drugbank.com/drugs/DB14941
    Investigational

    BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).

  9. Drug

    BMS-929075

    go.drugbank.com/drugs/DB14950
    Investigational

    BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).

  10. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.